Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-04 bevacizumab + capecitabine in frail metastatic colorectal cancer
2007-002682-12Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and capecitabine in metastatic colorectal adenocarcinoma (mCRC), sponsored by Cancer Trials Ireland. Primary endpoint: Time to disease progression by RECIST. Started May 2007; status: completed.
02
Drugs
bevacizumabcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2007-002682-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002682-12.